Collegium Pharmaceutical, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| COLL | AQST | PCRX | 42C.SI | LUP.F | 0950.HK | |
|---|---|---|---|---|---|---|
| Market cap | 770.59M | 476.94M | 1.45B | 515.12M | 762.19M | 638.89M |
| P/E (TTM) | 18.6 | — | 104.0 | — | 18.8 | 5.4 |
| Forward P/E | 3.3 | -6.7 | 10.5 | 247.4 | — | 7.8 |
| Price/book | 2.5 | -13.8 | 2.2 | 33.6 | 0.4 | 0.3 |
| Dividend yield | — | — | — | — | — | 6.51% |
| 1-year change | −33.81% | −35.33% | +66.54% | +259.26% | −48.27% | −41.58% |
| Today | −0.25% | −2.06% | +0.03% | −3.09% | +3.87% | +0.93% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All COLL news ›Collegium Pharmaceutical (COLL) Q3 earnings: what to expect
Collegium Pharmaceutical missed analysts’ revenue expectations last quarter, reporting revenues of $199.9 million, up 6.3% year on year. It was a softer quarter for the company, with full-year revenue and EBITDA guidance missing analysts’…
Collegium Pharmaceutical Announces Seven ADHD Abstracts Accepted for AACAP and NEI Fall Congresses
Collegium Pharmaceutical will present seven abstracts on ADHD at upcoming scientific congresses, focusing on pediatric and adult research. Collegium announced seven abstracts accepted for presentation at two scientific congresses focusing…
H.C. Wainwright Reaffirms Their Buy Rating on Collegium Pharmaceutical (COLL)
H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Collegium Pharmaceutical today and set a price target of $60.00. According to TipRanks, Folkes is a 3-star analyst with an average return of 1.7% and a 43.64% success rate.…
Collegium Pharmaceutical initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Collegium Pharmaceutical (COLL) with an Outperform rating and $50 price target The market continues to value ... Collegium Pharmaceutical initiated with an Outperform at Oppenheimer Oppenheimer initiated…
Collegium Pharmaceutical (COLL) Receives a Buy from Barclays
Barclays analyst Jenna Davidner maintained a Buy rating on Collegium Pharmaceutical today and set a price target of $48.00. Davidner covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Xeris Pharmaceuticals,…
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut
(NASDAQ:COLL) Seeking Alpha - Collegium Pharmaceutical is rated a high-risk Buy after a sharp guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. - ADHD drugs Jornay PM and AZSTARYS now a
Sanofi (NASDAQ:SNY) and Collegium Pharmaceutical (NASDAQ:COLL) Critical Review
Posted by Sarita Garza on Oct 11th, 2026 Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) and Sanofi (NASDAQ:SNY – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses…
All Transcripts on Middle East Pharmaceutical Industries Company (4016)
Find all the latest transcripts on Middle East Pharmaceutical Industries Company Transcripts Middle East Pharmaceutical Industries Company All financial news and data tailored to specific country editions
Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Year 2026
Collegium Pharmaceutical, Inc. revised earnings guidance for the year 2026. The company now expects Product Revenues, Net to be $825 million to $855 million against previous guidance of $865 million... Collegium Pharmaceutical, Inc.…
Transcript : Collegium Pharmaceutical, Inc., Q2 2026 Earnings Call, Aug 06, 2026
Presentation Operator MessageOperator Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that this conference Transcript : Collegium Pharmaceutical,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com15
- markets.businessinsider.com5
- ir.collegiumpharma.com1
- roastbrief.us1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 24 articles, not a forecast.